Aurum Biosciences

About:

Aurum Biosciences has develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need.

Website: http://www.aurumbiosciences.com/

Twitter/X: aurumbioscience

Top Investors: Scottish Enterprise, TRICAPITAL, InnoScot Health, Scottish Investment Bank, Scottish Health Innovations

Description:

AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.

Total Funding Amount:

4.4M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Glasgow, Glasgow City, United Kingdom

Founded Date:

2015-01-01

Founders:

Graeme Deuchar

Number of Employees:

1-10

Last Funding Date:

2024-01-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai